Travere Therapeutics (TVTX) Equity Ratio (2016 - 2025)
Travere Therapeutics' Equity Ratio history spans 15 years, with the latest figure at 0.19 for Q4 2025.
- For Q4 2025, Equity Ratio rose 90.82% year-over-year to 0.19; the TTM value through Dec 2025 reached 0.19, up 90.82%, while the annual FY2025 figure was 0.19, 90.82% up from the prior year.
- Equity Ratio reached 0.19 in Q4 2025 per TVTX's latest filing, up from 0.14 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.47 in Q1 2021 to a low of 0.06 in Q3 2024.
- Average Equity Ratio over 5 years is 0.2, with a median of 0.17 recorded in 2023.
- Peak YoY movement for Equity Ratio: tumbled 117.97% in 2024, then soared 326.23% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.39 in 2021, then plummeted by 83.62% to 0.06 in 2022, then soared by 299.52% to 0.25 in 2023, then crashed by 60.94% to 0.1 in 2024, then skyrocketed by 90.82% to 0.19 in 2025.
- Per Business Quant, the three most recent readings for TVTX's Equity Ratio are 0.19 (Q4 2025), 0.14 (Q3 2025), and 0.06 (Q2 2025).